161 related articles for article (PubMed ID: 37839939)
41. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan KM; Elmeshhadany AY; Shabila NP
Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
[TBL] [Abstract][Full Text] [Related]
43. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.
Kuykendall AT; Ball S; Mora B; Mo Q; Al Ali N; Maffioli M; Auteri G; Mazzoni C; Palumbo GA; Duminuco A; Longo A; Elli EM; Passamonti F; Palandri F; Komrokji R
JCO Precis Oncol; 2024 Mar; 8():e2300593. PubMed ID: 38484210
[TBL] [Abstract][Full Text] [Related]
44. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.
Mesa RA; Su Y; Woolfson A; Prchal JT; Turnbull K; Jabbour E; Scherber R; Shields AL; Krohe M; Ojo F; Pompilus F; Cappelleri JC; Harrison C
Health Qual Life Outcomes; 2019 Apr; 17(1):61. PubMed ID: 30975150
[TBL] [Abstract][Full Text] [Related]
45. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
46. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
47. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
48. Low-dose ruxolitinib shows effective in treating myelofibrosis.
Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
[TBL] [Abstract][Full Text] [Related]
49. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
Palmer J; Mesa R
Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
51. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
52. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
[TBL] [Abstract][Full Text] [Related]
53. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
54. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
55. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
56. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10
Talpaz M; Prchal J; Afrin L; Arcasoy M; Hamburg S; Clark J; Kornacki D; Colucci P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):336-346. PubMed ID: 34911667
[TBL] [Abstract][Full Text] [Related]
57. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
Breccia M; Baratè C; Benevolo G; Bonifacio M; Elli EM; Guglielmelli P; Maffioli M; Malato A; Mendicino F; Palumbo GA; Pugliese N; Rossi E; Rumi E; Sant'Antonio E; Ricco A; Tiribelli M; Palandri F
Ann Hematol; 2020 Jan; 99(1):65-72. PubMed ID: 31832751
[TBL] [Abstract][Full Text] [Related]
58. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Yacoub A; Odenike O; Verstovsek S
Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
[TBL] [Abstract][Full Text] [Related]
59. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
60. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]